326 related articles for article (PubMed ID: 32036574)
1. Automation Opportunities in Pharmacovigilance: An Industry Survey.
Ghosh R; Kempf D; Pufko A; Barrios Martinez LF; Davis CM; Sethi S
Pharmaceut Med; 2020 Feb; 34(1):7-18. PubMed ID: 32036574
[TBL] [Abstract][Full Text] [Related]
2. Industry Perspective on Artificial Intelligence/Machine Learning in Pharmacovigilance.
Kassekert R; Grabowski N; Lorenz D; Schaffer C; Kempf D; Roy P; Kjoersvik O; Saldana G; ElShal S
Drug Saf; 2022 May; 45(5):439-448. PubMed ID: 35579809
[TBL] [Abstract][Full Text] [Related]
3. Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks.
van Stekelenborg J; Kara V; Haack R; Vogel U; Garg A; Krupp M; Gofman K; Dreyfus B; Hauben M; Bate A
Drug Saf; 2023 Jan; 46(1):39-52. PubMed ID: 36565374
[TBL] [Abstract][Full Text] [Related]
4. Sorting Through the Safety Data Haystack: Using Machine Learning to Identify Individual Case Safety Reports in Social-Digital Media.
Comfort S; Perera S; Hudson Z; Dorrell D; Meireis S; Nagarajan M; Ramakrishnan C; Fine J
Drug Saf; 2018 Jun; 41(6):579-590. PubMed ID: 29446035
[TBL] [Abstract][Full Text] [Related]
5. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.
Stergiopoulos S; Fehrle M; Caubel P; Tan L; Jebson L
Pharmaceut Med; 2019 Dec; 33(6):499-510. PubMed ID: 31933240
[TBL] [Abstract][Full Text] [Related]
6. Utilizing Advanced Technologies to Augment Pharmacovigilance Systems: Challenges and Opportunities.
Lewis DJ; McCallum JF
Ther Innov Regul Sci; 2020 Jul; 54(4):888-899. PubMed ID: 32557311
[TBL] [Abstract][Full Text] [Related]
7. Integrating Regulatory Drug Label Information to Facilitate Evaluation of Adverse Events in Pharmacovigilance.
Hui TZ
Curr Drug Saf; 2020; 15(2):124-130. PubMed ID: 32091345
[TBL] [Abstract][Full Text] [Related]
8. Training Augmented Intelligent Capabilities for Pharmacovigilance: Applying Deep-learning Approaches to Individual Case Safety Report Processing.
Abatemarco D; Perera S; Bao SH; Desai S; Assuncao B; Tetarenko N; Danysz K; Mockute R; Widdowson M; Fornarotto N; Beauchamp S; Cicirello S; Mingle E
Pharmaceut Med; 2018; 32(6):391-401. PubMed ID: 30546259
[TBL] [Abstract][Full Text] [Related]
9. Validating Intelligent Automation Systems in Pharmacovigilance: Insights from Good Manufacturing Practices.
Huysentruyt K; Kjoersvik O; Dobracki P; Savage E; Mishalov E; Cherry M; Leonard E; Taylor R; Patel B; Abatemarco D
Drug Saf; 2021 Mar; 44(3):261-272. PubMed ID: 33523400
[TBL] [Abstract][Full Text] [Related]
10. Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility.
Muñoz MA; Dal Pan GJ; Wei YJ; Delcher C; Xiao H; Kortepeter CM; Winterstein AG
Drug Saf; 2020 Apr; 43(4):329-338. PubMed ID: 31912439
[TBL] [Abstract][Full Text] [Related]
11. "Artificial Intelligence" for Pharmacovigilance: Ready for Prime Time?
Ball R; Dal Pan G
Drug Saf; 2022 May; 45(5):429-438. PubMed ID: 35579808
[TBL] [Abstract][Full Text] [Related]
12. What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations?
Pariente A; Micallef J; Lahouegue A; Molimard M; Auffret M; Chouchana L; Denis B; Faillie JL; Grandvuillemin A; Letinier L; Pierron E; Pons C; Pujade I; Rubino H; Salvo F
Therapie; 2023; 78(1):131-143. PubMed ID: 36572627
[TBL] [Abstract][Full Text] [Related]
13. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
14. A Risk-Based Approach for Safety Case Follow-up of Adverse Event Reports in Pharmacovigilance.
Vemula GK; Badale P; Mavrogenis P; Lalande-Luesink I; Borkowski M; Lewis DJ
Adv Ther; 2024 Jan; 41(1):82-91. PubMed ID: 37919600
[TBL] [Abstract][Full Text] [Related]
15. Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania.
Barry A; Olsson S; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; Bergman U; van Puijenbroek E; Gurumurthy P; Aklillu E
Drug Saf; 2020 Apr; 43(4):339-350. PubMed ID: 31919794
[TBL] [Abstract][Full Text] [Related]
16. Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing.
Schmider J; Kumar K; LaForest C; Swankoski B; Naim K; Caubel PM
Clin Pharmacol Ther; 2019 Apr; 105(4):954-961. PubMed ID: 30303528
[TBL] [Abstract][Full Text] [Related]
17. Innovations for the future of pharmacovigilance.
Almenoff JS
Drug Saf; 2007; 30(7):631-3. PubMed ID: 17604419
[TBL] [Abstract][Full Text] [Related]
18. Leveraging Machine Learning to Facilitate Individual Case Causality Assessment of Adverse Drug Reactions.
Cherkas Y; Ide J; van Stekelenborg J
Drug Saf; 2022 May; 45(5):571-582. PubMed ID: 35579819
[TBL] [Abstract][Full Text] [Related]
19. Implementation and comparison of two text mining methods with a standard pharmacovigilance method for signal detection of medication errors.
Eskildsen NK; Eriksson R; Christensen SB; Aghassipour TS; Bygsø MJ; Brunak S; Hansen SL
BMC Med Inform Decis Mak; 2020 May; 20(1):94. PubMed ID: 32448248
[TBL] [Abstract][Full Text] [Related]
20. Individual case safety reports--how to determine the onset date of an adverse reaction: a survey.
Klepper MJ; Edwards B
Drug Saf; 2011 Apr; 34(4):299-305. PubMed ID: 21417502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
